Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK111 Injection in Moderate-to-Severe Plaque Psoriasis
CTR20232697Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of gumokimab in plaque psoriasis, sponsored by Akeso, Inc.. Started Aug 2023; status: completed.
02
Drugs
gumokimab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on CTR20232697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232697.